ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
4.890
-0.130 (-2.59%)
At close: Sep 18, 2026, 4:00 PM EDT
4.860
-0.030 (-0.61%)
After-hours: Sep 18, 2026, 4:10 PM EDT
ImageneBio Revenue
In the year 2025, ImageneBio had annual revenue of $800.00K, down -77.14%.
Revenue (ttm)
$800.00K
Revenue Growth
-77.14%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
55.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 800.00K | -2.70M | -77.14% |
| Dec 31, 2024 | 3.50M | -5.66M | -61.79% |
| Dec 31, 2023 | 9.16M | -6.46M | -41.35% |
| Dec 31, 2022 | 15.62M | -15.37M | -49.59% |
| Dec 31, 2021 | 30.99M | 21.79M | 237.01% |
| Dec 31, 2020 | 9.19M | -4.56M | -33.15% |
| Dec 31, 2019 | 13.75M | 12.76M | 1,289.19% |
| Dec 31, 2018 | 990.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 151.18M |
| Xilio Therapeutics | 64.09M |
| Apollomics | 8.84M |
| Hyperion DeFi | 1.40M |
| Clene | 197.00K |
| Serina Therapeutics | 130.00K |
| eXoZymes | -700.00 |
IMA News
- 12 days ago - ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York - GlobeNewsWire
- 4 weeks ago - ImageneBio initiated with a Buy at H.C. Wainwright - TheFly
- 4 weeks ago - ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - ImageneBio registers to sell 5.77M shares of common stock for holders - TheFly
- 6 weeks ago - ImageneBio files $200M mixed securities shelf - TheFly
- 6 weeks ago - ImageneBio reports Q2 EPS (63c), consensus (98c) - TheFly
- 6 weeks ago - ImageneBio Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - ImageneBio appoints Matt Robbins as general counsel - TheFly